Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-28 | Q1 FY262026-03-29 | Q4 FY252025-12-31 | Q3 FY252025-09-28 | Q2 FY252025-06-29 | Q1 FY252025-03-30 | Q4 FY242024-12-31 | Q3 FY242024-09-29 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | $13.72B | $17.76B | $17.70B |
| Cost of revenue | $4.09B | $3.55B | $5.27B | $4.17B | $3.78B | $2.85B | $5.91B | $5.26B |
| Gross profit | $10.94B | $10.90B | $12.29B | $12.48B | $10.88B | $10.87B | $11.86B | $12.44B |
| Gross margin | 72.8% | 75.4% | 70.0% | 74.9% | 74.2% | 79.3% | 66.7% | 70.3% |
| Research and development | $2.81B | $2.49B | $3.21B | $2.55B | $2.48B | $2.20B | $3.04B | $2.60B |
| Selling, general and administrative | $3.41B | $2.96B | $4.16B | $3.19B | $3.42B | $3.03B | $4.27B | $3.24B |
| Operating expenses | $7.88B | $6.87B | $9.42B | $8.63B | $7.09B | $7.13B | $9.51B | $7.48B |
| Operating income | $3.06B | $4.03B | $2.87B | $3.85B | $3.78B | $3.74B | $2.35B | $4.96B |
| Operating margin | 20.4% | 27.9% | 16.3% | 23.1% | 25.8% | 27.3% | 13.2% | 28.0% |
| EBITDA | $5.16B | $5.88B | $5.37B | $7.19B | $5.39B | $6.04B | $4.98B | $7.04B |
| Interest income | $113.00M | $0 | $0 | — | $156.00M | $0 | $0 | — |
| Interest expense | −$667.00M | $0 | $0 | — | −$654.00M | $0 | $0 | — |
| Income before taxes | −$653.00M | $3.17B | −$1.64B | $3.33B | $3.04B | $2.79B | −$10.00M | $4.72B |
| Income taxes | −$407.00M | $461.00M | −$2.00M | −$216.00M | $141.00M | −$189.00M | −$421.00M | $234.00M |
| Net income | −$238.00M | $2.70B | −$1.64B | $3.55B | $2.93B | $2.97B | $418.00M | $4.47B |
| Net margin | -1.6% | 18.7% | -9.3% | 21.3% | 20.0% | 21.7% | 2.4% | 25.3% |
| EPS, basic | −$0.04 | $0.47 | −$0.29 | $0.62 | $0.51 | $0.52 | $0.07 | $0.79 |
| EPS, diluted | −$0.04 | $0.47 | −$0.29 | $0.62 | $0.51 | $0.52 | $0.07 | $0.78 |
| Diluted shares | 5.70B | 5.73B | 5.72B | 5.71B | 5.71B | 5.71B | 5.70B | 5.71B |
Figures describe Pfizer shares, not any token. As of Aug 4, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.